Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaprodine SCHEMBL25053 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL248367 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Alphaprodine SCHEMBL25054 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL394431 | 0.99 | LMNA (1.00) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Alphaprodine SCHEMBL8818643 | 0.99 | LMNA (1.00) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL1649307 | 0.97 | LMNA (0.93) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Proheptazine SCHEMBL25539 | 0.93 | LMNA (0.84) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL11383571 | 0.89 | LMNA (0.78) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL4283575 | 0.88 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL8977860 | 0.88 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY | 2024-01-04 | — | — | US | claimed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4255893-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | The Johns Hopkins University (US) | 2023-10-11 | — | — | EP | claimed |
| WO-2023187225-A1 | ALKALINE INTRAORAL PRODUCTS | AMPLICON AB (SE) | 2023-10-05 | — | — | WO | claimed |
| US-11527315-B2 | Drug device configured for wireless communication | POP TEST ABUSE DETERRENT TECHNOLOGY LLC (US) | 2022-12-13 | — | — | US | claimed |
| WO-2022119823-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-09 | — | — | WO | claimed |
| US-20040254207-A1 | Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives and caffeine | NATIONAL SCIENCE FOUNDATION | 2004-12-16 | — | — | US | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004043460-A1 | SYNERGISTIC COMBINATIONS WITH ANALGESIC PROPERTIES COMPRISING N-ACYLATED 4-HYDROXYPHENYLAMINE DERIVATIVES | LSU MEDICAL CENTER FOUNDATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-20040092541-A1 | SYNERGISTIC COMBINATIONS INCLUDING N-ACYLATED 4-HYDROYPHENYLAMINE DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2004-05-13 | — | — | US | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11527315-B2 | Drug device configured for wireless communication | CYP2D6, CYP2B6, PTGDR | LMNA 3860/4885DRD3 420/4885NPSR1 19/4885 |
| US-20040254207-A1 | Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives and caffeine | OPRK1, OPRM1, OPRD1 | LMNA 3906/4885DRD3 671/4885NPSR1 328/4885 |
| US-20040092541-A1 | SYNERGISTIC COMBINATIONS INCLUDING N-ACYLATED 4-HYDROYPHENYLAMINE DERIVATIVES | OPRK1, OPRM1, OPRD1 | LMNA 4660/4885DRD3 405/4885NPSR1 149/4885 |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | MRGPRX1, MRGPRX4, MRGPRX2 | LMNA 4368/4885DRD3 1269/4885NPSR1 117/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | LMNA 4237/4885DRD3 4801/4885NPSR1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.